| Similar Articles |
|---|
 |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better.   |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
February 28, 2011
Brian Orelli |
Pharma's Newest Acquisition Targets Share buybacks are in at big pharma companies. Does it mean that licensing deals are out? |
BusinessWeek
June 13, 2005 |
Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison. |
Pharmaceutical Executive
September 1, 2008
Walter Armstrong |
The M&A Numbers Young & Partners crunches pharma's filings for the first half of '08. |
The Motley Fool
April 29, 2005
Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc. |
The Motley Fool
December 20, 2007
Brian Orelli |
2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
Pharmaceutical Executive
May 1, 2009 |
The Shakeout When it comes to licensing in this market, there are winners and losers. Learn the new rules of the game. |
The Motley Fool
January 28, 2008
Brian Lawler |
A Great Way to Recession-Proof Your Portfolio If you want a recession resistant portfolio, invest in large cap pharmaceuticals. |
Pharmaceutical Executive
June 1, 2011 |
2011 Dealmakers Outlook With Yankee stadium as the backdrop, Pharm Exec convened on March 29 its annual panel of eight business development experts to crack the bat on best practice in licensing for the year ahead. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market. |
Pharmaceutical Executive
September 1, 2010 |
Pharm Exec's Ninth Annual Industry Audit Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Knowledge@Wharton
March 26, 2003 |
Health Care Finance Industry Plagued by Lack of Funding, Focus In today's health care finance environment, early financing rounds are harder to fund and the market for initial public financings is dead, with no revival expected anytime soon. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
Bio-IT World
February 2006
G. Steven Burrill |
Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006... |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
Financial Planning
April 1, 2006
Donald Jay Korn |
Rx for Investing Healthcare stocks may cure investors' ills over the long term, but the current prognosis is less clear. For clients in diversified funds, planners should decide whether additional healthcare exposure is justified, through individual stocks or specialized funds. |
The Motley Fool
August 18, 2008
Zoe Van Schyndel |
Funds for a Sick Economy? The biotech sector has been a sleeper with positive returns. Take a look at two biotech mutual funds that are performance leaders. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Future Biotech Winners Will Help Nurses Clean Up Less (Stuff) It's not enough anymore to prove your drug is safe and effective enough to pass muster with the FDA. Now it's also about proving a drug can generate savings and value for the health care system. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
Chemistry World
February 2012 |
Navigating the stormy seas of pharma In the pharmaceutical and biotech sector, quality navigation is becoming an essential process for identifying the best route to take in order to guide business effectively in a dramatically changing environment. |
Chemistry World
February 2008
Nuala Moran |
The Chemistry of Private Equity Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies? |
The Motley Fool
February 25, 2004
Brian Gorman |
Merck's Slow and Steady The big pharma's cautious approach could pay off in the industry. |
Pharmaceutical Executive
October 1, 2005
Mark J. Ahn |
It's All Academic: Biotechs Looking to Universities Pharmaceuticals and academic institutions are forming alliances at an increasing rate to exploit the promise of emerging biological insights. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
Pharmaceutical Executive
July 10, 2014
William Looney |
Pharm Exec's 2014 Dealmakers Outlook As the pacing picks up around dealmaking as the alternative to organic growth, Pharm Exec brings together experts from big Pharma and biotech to dissect the road ahead. |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
Pharmaceutical Executive
June 1, 2012 |
2012 Dealmakers Outlook With Yankee Stadium as the backdrop, Pharm Exec convened on its annual panel of heavy hitters in business development to crack the bat on best practices in licensing and for the year ahead. |
Managed Care
September 2005
John Carroll |
Plans Struggle for Control of Specialty Pharma Costs Biotech drugs are a quickly growing component of health plan budgets. Here are the latest management techniques. |
Bio-IT World
May 2006
Mark D. Uehling |
Bio-IT World CTMS Survey An online survey of the clinical trial management system market reveals some divergences between how the pharma/biotech folks and the contract research folks see the CTMS landscape. Are our respondents happy with the CTMS landscape? |
The Motley Fool
July 12, 2004
Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good. |
Pharmaceutical Executive
December 1, 2008
Walter Armstrong |
The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future. |
The Motley Fool
September 3, 2004
Charly Travers |
MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
The Motley Fool
April 5, 2011
Frank Vinluan |
Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat. |
The Motley Fool
December 21, 2004
Charly Travers |
Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
Bio-IT World
May 19, 2004
Branca, Hoffer & Nambiar |
Keeping an Even Keel Bland first quarter was punctuated by HGS mini-drama: Biotech guru Steven Burrill hailed the first quarter of 2004 as biotech's best funding quarter in the industry's 30-year history. But it was also a strange one. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
The Motley Fool
April 19, 2006
Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
Pharmaceutical Executive
October 1, 2005
Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool
January 19, 2012
Sean Williams |
No Vacancy: Workers Need Not Apply to This Sector Pharmaceutical and biotech layoffs are kicking into high gear. |
